Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
This year, more than 5 million Americans will be diagnosed with Heart Valve Disease. All too often, for Black patients with certain forms of the disease this can be a death sentence, with patients from minority communities facing significantly higher mortality rates than their white counterparts. The most common form of this disease is aortic stenosis (AS), where the aortic valve narrows and weakens the heart. While common, AS can be deadly, and one in six patients will have a more aggressive form called symptomatic severe aortic stenosis (SSAS), that can be fatal within two years without treatment. Diseases like SASS and other chronic diseases lay bare stark inequities in our health care system, in which our Black patients are disproportionately impacted. When we see patients with SSAS, treatment options include two approaches to repair their failing valve, one that involves open-heart surgery and one that is minimally invasive. The latter, transcatheter aortic valve replacement (TAV
Use of mental health and substance use services fell by double digits last year for adults and children covered by Medicaid and CHIP, according to a report by the Centers for Medicare and Medicaid Services.
Dr V Antoine Keller, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try
Heron Therapeutics is positioning its drug, Zynrelef, as a way to help patients avoid addictive opioid painkillers following surgery. The extended-release formulation offers analgesic effects over 72 hours when postsurgical pain is most severe and more likely to require pain management medication.
Shares0
The FDA has approved a Heron Therapeutics combination drug developed to treat postsurgical pain and help patients avoid the need for opioid painkillers, a regulatory decision that comes after the agency twice turned down applications from the biotech.